Skip to content
akaturk Academic measurement

Article detail · 2016

Prognostic factors and a new prognostic index model for children and adolescents with Hodgkin s lymphoma who underwent autologous hematopoietic stem cell transplantation a multicenter study of the Turkish Pediatric BMT Study Group

Journal

Turkish Journal of Hematology

ISSN 1300-7777

YÖKSİS OpenAlex Open access · diamond SJR Q4 JCR Q4 TR Index Citations 1 Percentile 58.5% FWCI 0.23
Year
2016
Type
article

Data source split

  • YÖKSİS YÖKSİS article record
  • YÖKSİS venue Turkish Journal of Hematology
  • Catalog match (ISSN) Turkish Journal of Hematology
  • OpenAlex OpenAlex enrichment (abstract, citations, topics)

Abstract

English (OpenAlex)

OBJECTIVE: The prognostic factors and a new childhood prognostic index after autologous hematopoietic stem cell transplantation (AHSCT) in patients with relapsed/refractory Hodgkin's lymphoma (HL) were evaluated. MATERIALS AND METHODS: The prognostic factors of 61 patients who underwent AHSCT between January 1990 and December 2014 were evaluated. In addition, the Age-Adjusted International Prognostic Index and the Childhood International Prognostic Index (CIPI) were evaluated for their impact on prognosis. RESULTS: The median age of the 61 patients was 14.8 years (minimum-maximum: 5-20 years) at the time of AHSCT. There were single relapses in 28 patients, ≥2 relapses in eight patients, and refractory disease in 25 patients. The chemosensitivity/chemorefractory ratio was 36/25. No pretransplant radiotherapy, no remission at the time of transplantation, posttransplant white blood cell count over 10x103/µL, posttransplant positron emission tomography positivity at day 100, and serum albumin of <2.5 g/dL at diagnosis were correlated with progression-free survival. No remission at the time of transplantation, bone marrow positivity at diagnosis, and relapse after AHSCT were significant parameters for overall survival. CONCLUSION: The major factors affecting the progression-free and overall survival were clearly demonstrated. A CIPI that uses a lactate dehydrogenase level of 500 IU/L worked well for estimating the prognosis. We recommend AHSCT at first complete remission for relapsed cases, and it should also be taken into consideration for patients with high prognostic scores at diagnosis.

Topics

  • Lymphoma Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia research
  • Hematopoietic Stem Cell Transplantation

Primary topic Lymphoma Diagnosis and Treatment

Authors

  1. VURAL KESİK
  2. erman ataş
  3. musa karakükçü
  4. SERAP AKSOYLAR
  5. MEHMET FATİH ERBEY KOÇ ÜNİVERSİTESİ
  6. NURDAN TAÇYILDIZ ANKARA ÜNİVERSİTESİ
  7. ALPAN KÜPESİZ
  8. HALDUN ÖNİZ
  9. GÜLYÜZ ÖZTÜRK
  10. MURAT ELLİ
  11. EMEL ÜNAL
  12. VOLKAN HAZAR